🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: CAB-LA Maintenance Dose

Found 11 matching trials

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

PHASE2

The purpose of this study was to assess the safety, tolerability, antiviral...

Status

Completed

Location

Alabama CRS

Start Date

2019-12-31

Trial ID

NCT03739996

Treatments Being Tested

Oral Cabotegravir (CAB)Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Long-Acting Injectable Cabotegravir (CAB LA)VRC07-523LS Standard of Care (SOC) ART

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

N/A

This study evaluates the real-world effectiveness and safety of a long-acti...

Status

Recruiting

Location

Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases

Start Date

2026-05-12

Trial ID

NCT07370649

Treatments Being Tested

Cabotegravir Plus Rilpivirine Long-Acting Injectable

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

PHASE3

The purpose of this study was to compare the efficacy, safety, and durabili...

Status

Active Not Recruiting

Location

Alabama CRS

Start Date

2019-03-28

Trial ID

NCT03635788

Treatments Being Tested

Standard of Care (SOC) Oral ART Oral RPV Oral CAB RPV-LA Loading Dose CAB-LA Loading Dose RPV-LA Maintenance Dose CAB-LA Maintenance Dose

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

PHASE3

This is a multicentre study carried out in participants living with human i...

Status

Completed

Location

GSK Investigational Site

Start Date

2023-07-06

Trial ID

NCT05917509

Treatments Being Tested

DTG/3TC Cabotegravir (CAB) LA Rilpivirine (RPV) LA

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

PHASE2

This study (POLAR), is designed to assess the antiviral activity and safety...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-09-24

Trial ID

NCT03639311

Treatments Being Tested

CAB LA RPV LA RPV DTG

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

PHASE3

This study will assess the pharmacokinetics, safety, tolerability, maintena...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-11-08

Trial ID

NCT05896748

Treatments Being Tested

Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

PHASE3

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted t...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-27

Trial ID

NCT02938520

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)ABC/DTG/3TC STR - Tablet DTG Tablet

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

PHASE3

This study is designed to assess the antiviral activity and safety of a two...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-11-09

Trial ID

NCT04542070

Treatments Being Tested

Cabotegravir Tablets Cabotegravir Injectable Suspension (CAB LA)Rilpivirine Tablets Rilpivirine Injectable Suspension (RPV LA)BIKTARVY Tablets (BIK)

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

PHASE3

This study will assess how effective, safe, and long-lasting a long-acting ...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2024-12-02

Trial ID

NCT06694805

Treatments Being Tested

CAB LA + RPV LA Oral ART

Previous Next